Alkem Q1 FY27 Results: Revenue ₹3,740 Cr, PBT ₹423 Cr

Board approves unaudited Q1 FY27 numbers

Alkem Laboratories Ltd. announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company said its Board of Directors approved both standalone and consolidated results at a meeting held on August 14, 2026. The update covers key operating and profitability metrics, along with earnings per share and comprehensive income. The filing also notes that the interim results were reviewed by the company’s statutory auditors. For investors tracking quarterly momentum, the release provides a detailed look at revenue, expenses, and profit for the period.

Consolidated performance: revenue, costs and profit

On a consolidated basis, Alkem reported revenue from operations of ₹3,740.15 crore for Q1 FY27. Total income stood at ₹3,892.90 crore, while total expenses were ₹3,120.91 crore. Profit before tax (PBT) was reported at ₹422.85 crore, and tax expense at ₹171.17 crore. Profit for the period was ₹251.11 crore, and total comprehensive income was ₹366.38 crore. The company also disclosed consolidated basic and diluted earnings per share (EPS) of ₹19.77 for the quarter.

Standalone performance: domestic business snapshot

For standalone operations, Alkem reported revenue from operations of ₹2,667.73 crore for the quarter ended June 30, 2026. Total income came in at ₹2,804.35 crore, while total expenses were ₹2,005.93 crore. Profit before tax from continuing operations was ₹798.42 crore, and tax expense was ₹228.44 crore. Profit for the period from continuing operations was ₹569.98 crore. Total comprehensive income for the standalone business was ₹567.42 crore.

Profit decline versus last year: what was reported

Alongside the financial statement line items, the coverage around the results also pointed to year-on-year pressure on profit. Alkem was reported to have posted consolidated net profit of ₹520 crore for the April-June quarter, a decline of 21.7% from ₹664 crore in the same period last year. The same reports described the quarter as one where profit fell despite revenue growth of about 10.9% to 11%. These figures were cited as headline performance markers for the quarter in market commentary. Alkem’s results communication, as referenced, also includes detailed consolidated and standalone statements approved by the board.

Earnings per share and comprehensive income

The company reported consolidated EPS (basic and diluted) of ₹19.77 for Q1 FY27. Comprehensive income was also disclosed in both sets of results, with consolidated total comprehensive income at ₹366.38 crore. Standalone total comprehensive income was reported at ₹567.42 crore. These lines are typically tracked because they incorporate items beyond profit for the period. The quarterly statement therefore gives a broader view of income for shareholders during the period.

Auditor review and governance disclosure

Alkem stated that Deloitte Haskins & Sells LLP provided an unmodified review report on the interim financial results. The company also highlighted that the results were unaudited and approved by the board. The meeting date, August 14, 2026, was specifically disclosed as the approval date for the Q1 FY27 numbers. Such disclosures are standard for quarterly reporting and help establish the review status of the results.

Capital expenditure plan: up to ₹75 crore at Baddi

Reports around the results also said Alkem approved an investment of up to ₹75 crore for a new manufacturing block at Baddi. The Baddi facility plan was presented alongside the Q1 performance update. While detailed project timelines and output targets were not provided in the available text, the approval itself signals a planned capacity or capability addition. This capex item was framed as a board-approved investment decision linked with the quarterly results announcement.

Other quarterly data points cited by trackers

Separate quarterly data tables cited in the coverage listed figures such as total revenue of ₹3,371.14 crore for a “Jun 25” period and ₹3,603.32 crore for “Mar 26,” along with associated operating and net income lines. The same snapshot also referenced total revenue from operations of ₹3,031.8 crore (stated as ₹30,318 million) with 2.2% year-on-year growth. Another note said revenue of ₹3,371.14 crore reflected a 7.23% quarter-on-quarter increase and 11.19% year-on-year growth, and cited operating profit of ₹179.20 crore with quarter-on-quarter and year-on-year increases. These figures appeared as part of external-style quarterly tracker summaries included in the provided text.

Key numbers at a glance

Market impact and analysis

The Q1 FY27 filing provides a clear split between consolidated and standalone performance, which matters because the two sets can move differently depending on subsidiary performance, costs, and tax lines. Consolidated revenue from operations of ₹3,740.15 crore sets the operating scale for the quarter, while total expenses of ₹3,120.91 crore indicate the cost base against that revenue. The reported headline net profit decline to ₹520 crore year-on-year, as cited in the coverage, puts focus on margins and profitability even when revenue grows. At the same time, the decision to approve up to ₹75 crore in investment at Baddi adds a capital allocation element to the quarter’s news flow. The unmodified auditor review report supports the compliance and reporting aspect of the update, with no modifications flagged in the review conclusion.

What to watch next

Alkem’s next scheduled earnings event referenced in the text was Q1 FY26-27 on August 14, 2026, which aligns with the board approval date disclosed for this quarter’s results. Investors will typically track subsequent updates for any further details on the Baddi manufacturing block investment and how it is reflected in future capex or operational disclosures. Any additional context on quarterly profit movement and the relationship between headline net profit commentary and the reported statement line items would also be monitored in future filings and investor communications.